Adaptive Biotechnologies issued upbeat 2026 guidance, forecasting MRD (minimal residual disease) revenue growth of at least 20% as adoption of its ClonoSeq assay expands across hematologic indications and community settings. The company expects test volume to rise roughly 30% year‑over‑year and plans slight average‑selling‑price increases tied to payer negotiations. Adaptive cited growing regulatory and clinical endorsement of MRD as a surrogate and trial endpoint as a tailwind for both commercial testing and biopharma clinical services. The firm also flagged EMR integrations and expanding registrational trial use as drivers of future demand. Broader implications include more blood‑based testing displacing invasive bone‑marrow assessments in some settings and higher visibility for MRD as a commercial diagnostic category.